High Circulating Vitamin D Levels Don’t Reduce Risk of Less Common Cancers (07/12/2010)
High levels of vitamin D in the bloodstream do not appear to reduce the risk of seven less common cancers: endometrial, esophageal, stomach, ovarian, pancreatic, kidney, and non-Hodgkin’s lymphoma.

Gemzar plus Avastin Does Not Improve Survival in Advanced Pancreatic Cancer (07/14/2010)
Results from a recent Phase III trial indicate that the addition of the targeted therapy Avastin® (bevacizumab) to the chemotherapy drug Gemzar® (gemcitabine) does not improve survival in advanced pancreatic cancer.

Afinitor Delays Progression of Advanced Pancreatic Neuroendocrine Tumors (07/08/2010)
In a recent Phase III trial, the targeted therapy Afinitor® (everolimus) more than doubled progression-free survival time among patients with advanced pancreatic neuroendocrine tumors (NET).

Improved Survival in Metastatic Pancreatic Cancer (06/24/2010)
It appears that the chemotherapy combination known as FOLFIRINOX may improve survival in metastatic pancreatic cancer over a current standard-of-care, Gemzar® (gemcitabine).

AMG 479 Produces Promising Results in Metastatic Pancreatic Cancer (06/07/2010)
According to the results of a Phase II clinical trial, treatment of metastatic pancreatic cancer with a combination of AMG 479 and Gemzar® (gemcitabine) resulted in better progression-free and overall survival than treatment with Gemzar alone. These results were presented at the 2010 annual meeting of the American Society of Clinical Oncology.

Depression May Persist With Metastatic Cancer (05/27/2010)
A substantial number of patients with metastatic cancer may suffer from depression which tends to persist and grow more severe toward the end of life, according to the results of a study published early online in the Journal of Clinical Oncology.